ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (...(ogy (VIB) and has exclusive rights tocer...),Health

Date:1/26/2009

ogy (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on the OMX Nordic Exchange Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances around these product candidates and is developing them in collaboration with partners including Genentech, Roche and ThromboGenics.

These projects are based around a competitive and in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abello, Bayer HealthCare, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA for antibody discovery. More information is available at http://www.bioinvent.com.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.00 a.m. CET, on 26 January, 2009.

    For further information, please contact:

    ThromboGenics NV

    Patrik De Haes
    Chief Executive Officer
    Tel: +32(0)16-75-13-10
    E-mail: patrik.dehaes@thrombogenics.com

    Stuart Laermer
    Chief Business Officer
    Tel: +1-212-201-0920
    E-mail: stuart.lae
'/>"/>
SOURCE  ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 
Related medicine technology :

1. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
4. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications
5. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
6. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
7. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
8. Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
11. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen